Physician profile
Taylor E Howell
NPI 1609641091
$2,049.65
in general payments reported to CMS, 2019-2025
18 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,023 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.40 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.11 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $202.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $142.38 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $109.94 | 2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $77.93 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $77.10 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $50.23 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $45.29 | 2024-2025 | Voquezna |
| Blueprint Medicines Corporation | $44.66 | 2024-2025 | Ayvakit |
| Intercept Pharmaceuticals, INC. | $39.38 | 2025 | |
| Braintree Laboratories, INC. | $35.30 | 2024-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $35.06 | 2024 | |
| Lilly USA, LLC | $33.09 | 2024 | Omvoh |
| Janssen Biotech, INC. | $32.76 | 2025 | Tremfya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.59 | 2025 | Xifaxan |
| Amgen INC. | $29.77 | 2025 | Uplizna |
| Ardelyx, INC. | $13.37 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.